Recombinant human lactoferrin to treat oral mucositis

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$349,929.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43DE015914-01
Agency Tracking Number:
DE015914
Solicitation Year:
2004
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2004-2
Small Business Information
AGENNIX, INC.
AGENNIX, INC., 8 GREENWAY PLZ, STE 910, HOUSTON, TX, 77046
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ATUL Varadhachary
(713) 552-1091
AVARADHACHARY@AGENNIX.COM
Business Contact:
RICK BARSKY
(713) 552-1091
RBARSKY@AGENNIX.COM
Research Institution:
n/a
Abstract
DESCRIPTION: Oral mucositis is a major dose-limiting toxic effect of intensive cancer chemotherapy and radiotherapy. In addition to the morbidity directly caused by severe oral mucositis, it can cause secondary morbidities by limiting oral intake or e

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government